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Abstract: Total hip arthroplasty is a common and important treatment
for osteoarthritis patients. Long-term cardiovascular effects elicited by
osteoarthritis or the implant itself remain unknown. The purpose of the
present study was to determine if there is an increased risk of late
cardiovascular mortality and morbidity after total hip arthroplasty
surgery.
A nationwide matched cohort study with data on 91,527 osteoar-
thritis patients operated on, obtained from the Swedish Hip Arthroplasty
Register. A control cohort (n¼ 270,688) from the general Swedish
population was matched 1:3 to each case by sex, age, and residence.
Mean follow-up time was 10 years (range, 7–21).
The exposure was presence of a hip replacement for more than 5
years. The primary outcome was cardiovascular mortality after 5 years.
Secondary outcomes were total mortality and re-admissions due to
cardiovascular events.
During the first 5 to 9 years, the arthroplasty cohort had a lower
cardiovascular mortality risk compared with the control cohort. How-
ever, the risk in the arthroplasty cohort increased over time and was
higher than in controls after 8.8 years (95% confidence interval [CI]
7.0–10.5). Between 9 and 13 years postoperatively, the hazard ratio
was 1.11 (95% CI 1.05–1.17). Arthroplasty patients were also more
frequently admitted to hospital for cardiovascular reasons compared
with controls, with a rate ratio of 1.08 (95% CI 1.06–1.11).
Patients with surgically treated osteoarthritis of the hip have an
increased risk of cardiovascular morbidity and mortality many years
after the operation when compared with controls.
(Medicine 95(6):e2662)
Abbreviations: CDR = Cause of Death Register, CI = confidence
interval, HR = hazard ratio, NPR = Swedish National Patient
Register, NSAID = nonsteroidal anti-inflammatory drugs, OPG =
osteoprotegerin, RANKL = receptor activator of nuclear factor k B
ligand, RANKL = receptor activator of nuclear factor k B ligand,
RR = rate ratio, SHAR = Swedish Hip Arthroplasty Register.
INTRODUCTION
T he pathogenesis of cardiovascular disease is causally relatedto inflammatory processes.1–3 Conditions associated with
inflammatoryactivity suchasrheumatoidarthritis4,5 orpoordental
health6,7 increase the risk of cardiovascular events.4,8 Parallel with
these insights, primary osteoarthritis has moved from being per-
ceived as a wear-and-tear condition to an inflammatory disease.9
Moreover, the most common treatment modality for symptomatic
osteoarthritis is joint replacement, a surgical procedure that
by itself induces inflammation.10 It is unknown how osteoarthritis
and its surgical treatment impact the cardiovascular system.
Worldwide more than 1 million patients receive a total hip
arthroplasty for osteoarthritis every year11 and, compared with
other common joint replacements, it is associated with a high
incidence of long-term inflammatory foreign-body tissue reac-
tions.12,13 In the early phase after total hip arthroplasty surgery,
mortality is increased when compared with the general popu-
lation,14 but this is later followed by a reduced mortality in
arthroplasty patients.15–17 The longest hitherto published fol-
low-up of mortality after total hip arthroplasty is for <13 years,
but long-term cardiovascular mortality and morbidity have not
been investigated beyond this period.
The aim of this study was to determine if there is a late
correlation between total hip arthroplasty and cardiovascular
events. We hypothesized that total hip arthroplasty patients
more than 5 years after index recorded surgery have an
increased risk for cardiovascular morbidity and mortality com-
pared with the general population.
METHODS
Design and Setting
We conducted a nationwide, matched, cohort study. During
the study period from 1992 to 2005, the average Swedish
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population was 8.9 million residents and a total of 256,298 total
hip arthroplasties were performed.18,19 Follow-up data on
deaths, causes of death, admissions to inpatient care, and
reasons for inpatient care, were collected until 2012.
Study Population
Cases
The arthroplasty cohort was recruited from the Swedish
Hip Arthroplasty Register (SHAR).19 We included only patients
operated on due to primary osteoarthritis with a cemented total
hip arthroplasty and excluded rare implants occurring <300
times in the SHAR. This was done to decrease surgeon selection
bias from implant fixation (cemented vs uncemented) and bias
from underlying hip diagnosis (primary or post-traumatic osteo-
arthritis or pediatric hip diseases) on mortality.
Controls
Each case was matched with 3 random controls that were
not present in the SHAR through Statistics Sweden’s registry
of the total population. These were matched to the arthro-
plasty cohort by sex, age 5 years, and residence. Residence
was defined as municipality, except for the 3 largest cities
(Stockholm, Malmo¨, and Gothenburg) where the municipality
was subdivided into parishes. The matching criteria were
chosen in order to limit socioeconomic confounding. All
register data were matched with their unique Swedish
personal identity numbers.
Data Sources
The cohorts were recruited from SHAR and Statistics
Sweden. The SHAR was founded in 1979 and provides pro-
spective observational nationwide data on hip arthroplasties.
Since 1992, personal identity numbers have been collected,
allowing for a patient-specific follow-up with a coverage of
97%.19 The registry is the second oldest arthroplasty quality
register in the world and captures 98% of all patients operated
on with a hip arthroplasty from all Swedish hospitals. Statistics
Sweden’s registry of the total population started in 1968 and
includes detailed information on all individuals’ baseline demo-
graphics and places of residence.
The outcomes were identified from the Swedish National
Patient Register (NPR) and the Cause of Death Register (CDR).
The NPR was started in 1964 and includes all inpatient care in
Sweden since 1987 with discharge codes according to ICD-9
and ICD-10 together with admission and discharge dates. The
proportion of patients with a given diagnosis where the registry
code is deemed correct (positive predictive value) is estimated
around 85% to 90%.20 The CDR includes the supposed under-
lying cause of death among Swedish citizens since 1961 and has
a completeness of 100%.
Variables
Exposure was defined by the presence of a total hip
arthroplasty. Apart from the matched age, sex, and residence,
we also adjusted for comorbidity calculated by cross-matching
with the NPR. ICD codes from admissions 2 years prior to
surgery, not including the surgery admission, were used in order
to estimate Charlson co-morbidity index. Apart from adjusting
for the index, we also adjusted separately for myocardial
infarction, chronic heart failure, cerebrovascular disease, dia-
betes mellitus, renal disease, and chronic obstructive pulmonary
disease. Adjustment for smoking was not possible, but we used
death due to lung cancer as a way to compare smoking
prevalence between the cases and controls as it highly correlates
with smoking. Furthermore, those with dementia, malignancies,
or hemiplegia were excluded from the models as these con-
ditions would most likely be more severe among the controls
due to selection bias.
Outcome
The primary outcome was death due to cardiovascular
disease as defined by the underlying main cause of death
(see Supplementary Code Table, http://links.lww.com/MD/
A687). Secondary outcomes were overall death, cardio-specific
deaths, cerebral-specific deaths, and hospital admissions due to
cardiovascular disease.
The start date for each case in the study was the surgery
date, while the controls were assigned to the corresponding
case’s date of surgery. For arthroplasty patients occurring twice
due to bilateral surgery, the first surgery date was chosen. End of
follow-up was defined as death or being alive on December 31,
2012. The minimum follow-up time was 5 years. For the
admission outcome, we included all admissions with a dis-
charge date 5 years or more after the start date, and prior to the
date of death. Admissions during which a patient died were
excluded in order to avoid reporting twice on the same outcome.
Statistical Analyses
We used the Cox proportional hazards regression for death
outcomes. The proportional hazards assumption was tested
using Grambsch and Therneau’s proposed test. We found a
violation for the exposure variable, Charlson Comorbidity
Index, and sex. We therefore stratified for the latter 2, while
the exposure variable was modeled through time-splits. Two
different approaches were chosen: The time was split into
periods of 5 years, and then each period was separately mod-
eled; the time was split into periods of 6 months and a single
model was fitted with an interaction term between the exposure
and the start-time for each split. Because the time was divided
into several splits, a patient can occur several times but only the
last period will contain the outcome event. For example, a
patient that died after 15 months will occur thrice; 0 to 6, 6 to 12,
and 12 to 15 months, but only the last period will contain the
event indicator (i.e., death). Since the start timewithin each split
is independent of the event status, it can be used as an interaction
term. In order to ascertain that increased mortality was not due
to reoperations, we censored cases in the arthroplasty group and
their corresponding controls at the time of reoperation in a
supplementary analysis.
The number of admissions was modeled using negative
binomial regression. The regression is similar to Poisson
regression, with the main exception that it allows for over-dis-
persion; in other words, the mean does not have to be equal to the
variance, by estimating an additional parameter. Each regression
model contained time as an offset term permitting the coefficients
to be interpreted as rate ratios (RRs) instead of counts.
All continuous variables were tested for nonlinearity. If
nonlinearity was indicated by a likelihood ratio-test resulting in
a P value below 0.05, the variable was modeled with a restricted
cubic spline. To avoid overfitting the regression model by
choosing too many knots, the number of spline knots was
chosen using the Bayesian information criterion.
All analyses were performed using R 3.2.2, using the rms-
package (v. 4.3-1) for survival modeling, using the MASS-
package (v. 7.3-44) for negative binomial regression.
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RESULTS
Study Participants
For the 362,215 participants in the study (91,527 arthro-
plasty group/270,688 control group) the mean age at start date
was 71 years and 58% were females (Table 1). The differences
between cases and controls were mostly negligible regarding
baseline demographics, although comorbidities and death due to
lung cancer were more frequent among the controls. The overall
mortality rate was 48% during the study; of these, 16% had died
due to cardiovascular causes (Table 2). The longest follow-up
time was 21 years; the interquartile range for the follow-up was
7 to 13 years.
Cardiovascular Mortality
The arthroplasty group exhibited a lower risk for cardio-
vascular mortality during the first 5 to 9 years, hazard ratio (HR)
0.94, 95% confidence interval (CI) 0.89 to 0.98. Thereafter, the
risk increased and between 9 and 13 years postoperatively, HR
was 1.11 (95% CI 1.05–1.16), where it remained elevated
during the remaining study period (Table 3, Figure 1). When
the time interaction was modeled using a spline, the cross-over
occurred after 8.8 years (95% CI 7.0–10.5) for cardiovascular
mortality and after 8.8 years (95% CI 8.3–9.3) for overall
mortality (Figure 1). Censoring at reoperation did not change
the mortality estimates (see Supplement, http://links.lww.com/
MD/A687).
Admissions for Cardiovascular Events
The numbers of admissions to inpatient care were
unevenly distributed between controls and cases, with arthro-
plasty patients being slightly more frequently admitted to
hospital for any cardiovascular reason than control individuals
(13.6% vs 12.0%, see Table 2). The most common reason for a
cardiovascular admission was a cardiac event, with 6.3% of all
arthroplasty patients admitted once or twice for cardiac events
as compared with 5.6% of all control individuals. Similarly, a
higher proportion of arthroplasty patients were admitted to
inpatient care more than twice due to cardiac events (2.0%)
when compared with control individuals (1.8%).
The adjusted risk of any admission to inpatient care due to
any cardiovascular reason was slightly higher for patients
operated on with a hip arthroplasty when compared with
controls (RR 1.08; 95% CI 1.06–1.11). Within the most com-
mon subcategory of cardiovascular admissions, cardiac admis-
sions, the adjusted RR was 1.06 (95% CI 1.03–1.10) for
arthroplasty patients when compared with controls (Table 4).
TABLE 1. Study Population Characteristics
Variable
Control
Group
(N ¼ 300,414)
Arthroplasty
Group
(N ¼ 91,973)
Age 71.1 (8.9) 70.6 (8.9)
Female 174,334 (58.0%) 53,326 (58.0%)
Comorbidity
Cardiovascular
Cerebrovascular disease 6533 (2.2%) 1404 (1.5%)
Myocardial infarction 4043 (1.3%) 949 (1.0%)
Heart failure 3299 (1.1%) 761 (0.8%)
Other
Peripheral vascular
disease
1502 (0.5%) 300 (0.3%)
Malignancy

5722 (1.9%) 1627 (1.8%)
Metastasis

183 (0.1%) 45 (0.0%)
Chronic pulmonary
disease
2211 (0.7%) 444 (0.5%)
Dementia 1049 (0.3%) 66 (0.1%)
Peptic ulcer 1005 (0.3%) 582 (0.6%)
Rheumatic disease 748 (0.2%) 378 (0.4%)
Diabetes uncomplicated 704 (0.2%) 167 (0.2%)
Diabetes complicated 394 (0.1%) 49 (0.1%)
Renal disease 302 (0.1%) 94 (0.1%)
Mild liver disease 147 (0.0%) 49 (0.1%)
Severe liver disease 30 (0.0%) 8 (0.0%)
Paraplegia

47 (0.0%) 11 (0.0%)
Obesityy 37 (0.0%) 26 (0.0%)
Psychosesy 1105 (0.4%) 143 (0.2%)
Alcoholy 821 (0.3%) 222 (0.2%)
Charlson index
None 287,214 (95.6%) 88,640 (96.4%)
1–2 12,511 (4.2%) 3209 (3.5%)
3 689 (0.2%) 124 (0.1%)
Mean (SD) 0.08 (0.43) 0.07 (0.38)
Continuous variables are presented with mean and standard deviation.
SD ¼ standard deviation.
Excluded from the regression models.
yCalculated 5 y prior to surgery using the Elixhauser comorbidity
groups.
TABLE 2. Outcomes
Variable
Control
Group
(N ¼ 300,414)
Arthroplasty
Group
(N ¼ 91,973)
Mortality outcomes
Overall deaths due to
cardiovascular disease
23,169 (7.7%) 7100 (7.7%)
>5 y 15,167 (6.0%) 5152 (6.3%)
>10 y 6318 (4.4%) 2304 (4.9%)
>15 y 1537 (3.3%) 561 (3.6%)
All deaths 142,809 (47.5%) 42,022 (45.7%)
>5 y 93,861 (37.3%) 31,408 (38.6%)
>10 y 41,586 (29.2%) 15,198 (32.0%)
>15 y 10,801 (22.9%) 4082 (25.8%)
Lung cancer deaths 4060 (1.4%) 1054 (1.1%)
Admissions (5 y)
Number of cardiovascular
admissions
None 265,703 (88.4%) 79,467 (86.4%)
1–2 27,811 (9.3%) 9852 (10.7%)
3 6900 (2.3%) 2654 (2.9%)
Number of cardiac
admissions
None 279,070 (92.9%) 84,321 (91.7%)
1–2 16,476 (5.5%) 5820 (6.3%)
3 4868 (1.6%) 1832 (2.0%)
Number of cerebral
admissions
None 284,324 (94.6%) 86,102 (93.6%)
1–2 14,655 (4.9%) 5259 (5.7%)
3 1435 (0.5%) 612 (0.7%)
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Censoring at reoperation did not change the risk estimates (see
Supplement, http://links.lww.com/MD/A687).
DISCUSSION
In our nationwide cohort study of patients with surgically
treated osteoarthritis of the hip, we found an increased long-
term mortality and morbidity compared with controls. This
effect was mainly attributable to an increased risk of cardio-
vascular disease and an increased risk of admissions to hospital
care due to cardiovascular events. Our findings indicate an
association of surgically treated hip osteoarthritis with diseases
of the cardiovascular system, an association that—at least to our
knowledge—has not been described before. Hip arthroplasty
has, however, been associated to peripheral arterial disease at
long-term follow up.21 This study was performed in China
which implies that the association between total hip arthroplasty
and vascular disease may be generalized to different regions of
the world. The generalizability of the results on a global scale is
further supported by the fact that the Swedish hip arthroplasty
cohort differs marginally when compared with other large joint
arthroplasty cohorts in the Nordic countries22–24 as well as in
England,25 Australia,26 New Zeeland,27 and United States.28
While the type of implants may differ between countries, many
have higher re-operation rates than Sweden, and there is little
reason to believe that the cardiovascular effect would be smaller
in poorer performing implants.
The increased number of hospital admissions for arthro-
plasty patients due to cardiovascular reasons indicates an
increased overall cardiovascular morbidity for these individ-
uals. Both crude numbers and the adjusted risk of experiencing
an admission were increased for cases compared with controls.
Specifically, the risk of admission for any cardiovascular
reason—cardiac events, cerebral events, acute myocardial
infarction, thromboembolic events, and atherosclerotic
events—was increased. These findings are in agreement with
our finding of increased late cardiovascular mortality for
arthroplasty patients.
A major strength of our study is the large-scale population-
based cohort with the longest follow-up (21 years) of total hip
TABLE 3. Crude and Adjusted Estimates for the Full Period and 4 y Subperiods
Crude Adjusted
Variable Total Event HR 2.5% to 97.5% HR 2.5% to 97.5%
Cardiovascular mortality
Period: 5.0–8.9 y
Control 247,870 7307 (3.0%) 1 Ref 1 Ref
Arthroplasty 80,212 2288 (2.9%) 0.95 0.91–1.00 0.94 0.89–0.98
Period: 9.0–12.9 y
Control 166,826 4653 (2.8%) 1 Ref 1 Ref
Arthroplasty 55,421 1737 (3.1%) 1.12 1.06–1.18 1.10 1.04–1.16
Period: 13.0–16.9 y
Control 76,693 2347 (3.1%) 1 Ref 1 Ref
Arthroplasty 25,594 841 (3.3%) 1.08 1.00–1.17 1.07 0.99–1.16
Period: 17.0–21.0 y
Control 24,888 631 (2.5%) 1 Ref 1 Ref
Arthroplasty 8180 222 (2.7%) 1.07 0.92–1.25 1.10 0.94–1.28
Overall: 5.0–21.0 y
Control 247,870 14,938 (6.0%) 1 Ref 1 Ref
Arthroplasty 80,212 5088 (6.3%) 1.03 1.00–1.06 1.02 0.98–1.05
Overall mortality
Period: 5.0–8.9 y
Control 247,870 42,126 (17.0%) 1 Ref 1 Ref
Arthroplasty 80,212 12,684 (15.8%) 0.92 0.90–0.94 0.90 0.88–0.92
Period: 9.0–12.9 y
Control 166,826 29,769 (17.8%) 1 Ref 1 Ref
Arthroplasty 55,421 10,670 (19.3%) 1.07 1.05–1.10 1.05 1.03–1.08
Period: 13.0–16.9 y
Control 76,693 15,502 (20.2%) 1 Ref 1 Ref
Arthroplasty 25,594 5735 (22.4%) 1.11 1.08–1.14 1.11 1.07–1.14
Period: 17.0–21.0 y
Control 24,888 4498 (18.1%) 1 Ref 1 Ref
Arthroplasty 8180 1725 (21.1%) 1.16 1.10–1.23 1.19 1.13–1.26
Overall: 5.0–21.0 y
Control 247,870 91,895 (37.1%) 1 Ref 1 Ref
Arthroplasty 80,212 30,814 (38.4%) 1.01 1.00–1.02 1.00 0.99–1.01
At each subperiod those who have not experienced an event by the end are marked as alive at the end of the period. The adjusted HR contains all
variables as previously stated in the statistics section.
HR ¼ hazard ratio.
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arthroplasty patients ever published on a national level. Another
strength is the increased relative risk among patients despite
both self-selection and surgeon selection bias; in other words,
medically unfit patients will be less inclined for surgery. This is
also reflected in our baseline data where the Charlson comor-
bidities were more prevalent among controls than cases.
A paper by McMinn et al29 investigating mortality and
revision rates following hip arthroplasty raised a debate regard-
ing the importance of residual confounding and its role in the
interpretation of register-based research results.30 Some con-
founders might not be measured or even measurable; some
might be treated too simplistically. We believe that the residual
confounding in our study is considerably smaller than in many
previous studies since socioeconomic factors are accounted for,
at least to some extent.17,29
To the best of our knowledge, the analysis of the risk of
admission to inpatient care among hip arthroplasty patients and
controls is the first of its kind. The Swedish NPR that is the
source of our data is considered an instrument with high validity
and reliability,20 which gives us the unique opportunity to
analyze the underlying causes of admissions to hospital care
in a nationwide cohort of arthroplasty patients and
control individuals.
The major limitation to this study is a lack of adjustment
for obesity and smoking. Obesity increases the risk of devel-
oping osteoarthritis, even though the relationship is weaker for
FIGURE 1. Hazard ratio for total hip replacement patients comparedwith controls. The hazard increases over time; the arthroplasty group
exhibits at baseline, 5 y, a hazard lower than the controls. It then crosses over between 8 and 9 y, thereafter the hazard is greater for both
the cardiovascular and the overall mortality.
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hip osteoarthritis than for knee osteoarthritis. Obesity also
increases the risk of cardiovascular disease. Therefore, one
could perhaps expect a slight overrepresentation of cardio-
vascular morbidity among patients who have undergone
surgery for hip osteoarthritis compared with controls. Even
though there are ICD codes for obesity, these are rarely used
and therefore unreliable, thus the question of under-diag-
nosed obesity remains a limitation of our study. Smoking
increases the risk of cardiovascular disease and there are no
nationwide data on smoking habits. We therefore used lung
cancer as a proxy for comparing smoking in our cohorts, but
found no support for increased smoking habits within the
arthroplasty group.
Furthermore, the increased relative risk of cardiovascular
mortality and morbidity could be mediated through nonsteroidal
anti-inflammatory drugs (NSAID). Patients with hip osteoar-
thritis may often have had treatment with NSAIDs, both pre and
postoperatively, and this class of drugs is known to increase the
risk of cardiovascular disease.31,32 The overrepresentation of
cardiovascular morbidity in the arthroplasty group could thus be
explained by a higher intake of NSAIDs, a factor not possible to
control for.
Vascular calcification follows a pathological sequence of
events that has similarities to the physiological process of
osteogenesis.33 The receptor activator of nuclear factor k B
(RANK) is a member of the tumor necrosis factor receptor. It is
the receptor for the RANK-ligand (RANKL) and part of the
RANK/RANKL/osteoprotegerin (OPG) signaling pathway that
regulates osteoclast differentiation and activation.34 A disturb-
ance in the RANK pathway can raise calcification in blood
vessels.35 There is increasing evidence to suggest that both
osteopenia and vascular calcification may be linked.34 Although
it is established that the RANKL/OPG signaling pathway is
central to the processes regulating bone turnover in a wide
variety of medical conditions, there is now a strong clinical
association between coronary disease and serum OPG/RANKL
levels.36,37 Therefore, RANKL/OPG are recognized as having
equal importance in arterial calcification and osteolysis in
bone.34 In addition to associations of cardiovascular diseases
with bone and joint conditions, it is possible that the orthopedic
implant in itself can cause local and systemic inflammation. The
long-term bone remodeling and local osteopenia38 and osteo-
lysis12 around the implants used in total hip arthroplasty may
thus activate the RANK/RANKL/OPG pathway. Inflammation
associated with the hip implant would probably need an incu-
bation period of several years before the onset of clinical
manifestations, mainly affecting long-term survival. While
we chose 5 years as the starting point, the data suggest that
it takes at least 7 years before an increased risk of mortality is
observed. When discussing our finding, perhaps possible
increased inflammatory activity in patients with osteoarthritis
rather than the performed total hip arthroplasty could explain
the increased cardiovascular mortality in this group compared
with controls.39
CONCLUSIONS
We show that patients with surgically treated osteoarthritis
of the hip have an increased risk of cardiovascular morbidity
and mortality many years after the operation when compared
with control individuals matched for age, sex, and residence.
This association remains statistically significant after adjust-
ment for comorbidities. This observation may be indicative of
common disease pathways, and one of those could be enhanced
local or systemic inflammatory activity.
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